Close Menu

Try, Try, Try Again

Bucindolol, a beta-blocker that never made it to the market because a patient study showed it did not reduce the risk of death due to high blood pressure and heart failure, may be making a comeback. According to the Wall Street Journal, researchers report that heart failure patients with a specific genetic mutation given the drug were 48 percent less likely to die of heart-related problems and 44 percent less likely to be hospitalized, as compared to those given placebo.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.

Vox writes that lab mishaps involving pathogens are quite common.

In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.